ArticleIranian journal of basic medical sciences2026
Mitigation of sepsis-associated acute kidney injury by thymoquinone via targeting pyroptosis and attenuation of inflammation in C57BL/6 mice.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Acute kidney injury (AKI) is a severe, life-threatening complication of sepsis that often leads to renal failure. Thymoquinone, the main bioactive component of Materials and Methods: Thirty-two male C57BL/6 mice (20-25 g) were randomized into four groups: control, LPS, and two LPS groups treated with thymoquinone solubilized in Cremophor (1 or 10 mg/kg). AKI was induced by intraperitoneal injection of LPS (10 mg/kg). After 24 hr, blood samples were collected for blood urea nitrogen (BUN), cystatin C, and serum creatinine assays. Kidney homogenates were analyzed for malondialdehyde (MDA), superoxide dismutase (SOD), nitrite, interleukin-6 (IL-6), nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3), and caspase-1 levels. Results: Thymoquinone (10 mg/kg; PO) significantly decreased BUN ( Conclusion: Thymoquinone effectively attenuates LPS-induced AKI, likely by reducing oxidative stress, inhibiting pyroptosis and inflammation, and enhancing antioxidant defenses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.